Bullboard - Stock Discussion Forum MorphoSys 4 ADR Representing Ord Shs MOR

Alternate Symbol(s): MPSYF | MPHSF

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma... see more

Add To Watchlist

NDAQ:MOR - Post Discussion

MorphoSys 4 ADR Representing Ord Shs > MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product

View:

Post by whytestocks on Jan 30, 2024 3:30am

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product

Just In: $MOR MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityPreliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Anticipated 2024 OpEx in the range of &...MOR - MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

113